Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
03 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
Exosome Diagnostics Obviates Tissue Biopsies
17 avr. 2018 06h21 HE
|
Exosome Diagnostics
Waltham, MA, April 17, 2018 (GLOBE NEWSWIRE) -- This groundbreaking observation is presented as Late Breaking Research at the AACR Annual Meeting in Chicago on Tuesday by Dr Sudipto Chakrabortty....
Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs
21 mars 2018 07h41 HE
|
Exosome Diagnostics
Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs. As an internationally recognized...
Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients
20 mars 2018 07h46 HE
|
Exosome Diagnostics
Waltham, MA, March 20, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, recently published a study on the detection of the...
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
14 mars 2018 07h30 HE
|
Exosome Diagnostics
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration...
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
16 janv. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) announced today that it has added seven new patent applications to its existing Exclusive License Agreements with...
Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology
09 janv. 2018 07h46 HE
|
Exosome Diagnostics
Waltham, MA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has placed an Early Access version of its commercial Shahky system, which quantitively measures exosomal proteins, at...
Exosome Diagnostics Places Its First Early Access Shahky System within a Top 15 Pharmaceutical Laboratory
08 janv. 2018 07h56 HE
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
04 déc. 2017 07h33 HE
|
Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test
27 nov. 2017 08h16 HE
|
Exosome Diagnostics
Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...